| Literature DB >> 33846137 |
Ziying Han1, Hong Ye2, Jingjing Liang1, Ariel Shepley-McTaggart1, Jay E Wrobel2, Allen B Reitz2, Alison Whigham3, Katrina N Kavelish3, Michael S Saporito4, Bruce D Freedman1, Olena Shtanko3, Ronald N Harty1.
Abstract
Marburg virus (MARV) VP40 protein (mVP40) directs egress and spread of MARV, in part, by recruiting specific host WW domain-containing proteins via its conserved PPxY late (L) domain motif to facilitate efficient virus-cell separation. We reported previously that small-molecule compounds targeting the viral PPxY/host WW domain interaction inhibited VP40-mediated egress and spread. Here, we report on the antiviral potency of novel compound FC-10696, which emerged from extensive structure-activity relationship (SAR) of a previously described series of PPxY inhibitors. We show that FC-10696 inhibits egress of mVP40 virus-like particles (VLPs) and egress of authentic MARV from HeLa cells and primary human macrophages. Moreover, FC-10696 treated-mice displayed delayed onset of weight loss and clinical signs and significantly lower viral loads compared to controls, with 14% of animals surviving 21 days following a lethal MARV challenge. Thus, FC-10696 represents a first-in-class, host-oriented inhibitor effectively targeting late stages of the MARV life cycle.Entities:
Keywords: L domain; Marburg virus; Nedd4; PPxY motif; WW domain; antiviral therapeutic; budding; filovirus; host-oriented; virus-host interaction
Mesh:
Year: 2021 PMID: 33846137 PMCID: PMC8218653 DOI: 10.1128/AAC.00086-21
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191